Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.4952
-0.02-3.28%
At close: -
$0.5100
0.012.99%
After Hours: 7:16 PM EDT
Comments
Loading...
Oncolytics Biotech Analyst Ratings and Price Targets | NASDAQ:ONCY | Benzinga
Oncolytics Biotech Inc has a consensus price target of $5 based on the ratings of 6 analysts. The high is $9 issued by JonesTrading on May 24, 2023. The low is $3 issued by Maxim Group on March 10, 2025. The 3 most-recent analyst ratings were released by Maxim Group, HC Wainwright & Co., and RBC Capital on March 10, 2025, respectively. With an average price target of $4.33 between Maxim Group, HC Wainwright & Co., and RBC Capital, there's an implied 749.67% upside for Oncolytics Biotech Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
HC Wainwright & Co.
RBC Capital
Raymond James
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Oncolytics Biotech
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/10/2025 | Buy Now | 488.24% | Maxim Group | Jason McCarthy41% | $5 → $3 | Maintains | Buy | Get Alert |
| 03/10/2025 | Buy Now | 880.39% | HC Wainwright & Co. | Patrick Trucchio37% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/10/2025 | Buy Now | 880.39% | RBC Capital | Douglas Miehm41% | $6 → $5 | Maintains | Outperform | Get Alert |
| 02/03/2025 | Buy Now | 880.39% | HC Wainwright & Co. | Patrick Trucchio37% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 880.39% | HC Wainwright & Co. | Patrick Trucchio37% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2024 | Buy Now | 880.39% | HC Wainwright & Co. | Patrick Trucchio37% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2024 | Buy Now | 880.39% | HC Wainwright & Co. | Patrick Trucchio37% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 880.39% | HC Wainwright & Co. | Patrick Trucchio37% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | Buy Now | 488.24% | Raymond James | Rahul Sarugaser20% | → $3 | Initiates | → Outperform | Get Alert |
| 03/08/2024 | Buy Now | 880.39% | HC Wainwright & Co. | Patrick Trucchio37% | $5 → $5 | Maintains | Buy | Get Alert |
| 02/14/2024 | Buy Now | 880.39% | HC Wainwright & Co. | Patrick Trucchio37% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 01/19/2024 | Buy Now | 880.39% | HC Wainwright & Co. | Patrick Trucchio37% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 01/04/2024 | Buy Now | 880.39% | HC Wainwright & Co. | Patrick Trucchio37% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2023 | Buy Now | 880.39% | HC Wainwright & Co. | Patrick Trucchio37% | $15 → $5 | Maintains | Buy | Get Alert |
| 08/16/2023 | Buy Now | 2841.18% | HC Wainwright & Co. | Patrick Trucchio37% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/29/2023 | Buy Now | 2841.18% | HC Wainwright & Co. | Patrick Trucchio37% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/23/2023 | Buy Now | 880.39% | Canaccord Genuity | John Newman43% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | Buy Now | 2841.18% | HC Wainwright & Co. | Patrick Trucchio37% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/26/2023 | Buy Now | 2841.18% | HC Wainwright & Co. | Patrick Trucchio37% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2023 | Buy Now | 1664.71% | JonesTrading | Soumit Roy33% | → $9 | Initiates | → Buy | Get Alert |
| 03/14/2023 | Buy Now | 2841.18% | HC Wainwright & Co. | Patrick Trucchio37% | → $15 | Reiterates | → Buy | Get Alert |
| 03/06/2023 | Buy Now | 880.39% | Canaccord Genuity | John Newman43% | $6 → $5 | Maintains | Buy | Get Alert |
| 10/06/2022 | Buy Now | 488.24% | Maxim Group | Jason McCarthy41% | → $3 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Oncolytics Biotech (ONCY) stock?
The latest price target for Oncolytics Biotech (NASDAQ:ONCY) was reported by Maxim Group on March 10, 2025. The analyst firm set a price target for $3.00 expecting ONCY to rise to within 12 months (a possible 488.24% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Oncolytics Biotech (ONCY)?
The latest analyst rating for Oncolytics Biotech (NASDAQ:ONCY) was provided by Maxim Group, and Oncolytics Biotech maintained their buy rating.
When was the last upgrade for Oncolytics Biotech (ONCY)?
There is no last upgrade for Oncolytics Biotech
When was the last downgrade for Oncolytics Biotech (ONCY)?
There is no last downgrade for Oncolytics Biotech.
When is the next analyst rating going to be posted or updated for Oncolytics Biotech (ONCY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oncolytics Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oncolytics Biotech was filed on March 10, 2025 so you should expect the next rating to be made available sometime around March 10, 2026.
Is the Analyst Rating Oncolytics Biotech (ONCY) correct?
While ratings are subjective and will change, the latest Oncolytics Biotech (ONCY) rating was a maintained with a price target of $5.00 to $3.00. The current price Oncolytics Biotech (ONCY) is trading at is $0.51, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.